Insulin-Like Growth Factors and Insulin-Like Growth Factor–Binding Proteins and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial

The role of the insulin-like growth factor (IGF) axis and whether IGFs interact with androgen-suppressing agents in relation to prostate carcinogenesis is unclear. This nested case–control study (n = 1,652 cases/1,543 controls) examined whether serum IGF1, IGF2, IGFBP2, IGFBP3, and the IGF1:IGFBP3 ratio were associated with prostate cancer in the Prostate Cancer Prevention Trial (PCPT), a randomized, placebo-controlled trial of finasteride for prostate cancer prevention. Presence or absence of cancer was determined by prostate biopsy. Baseline serum was assayed for IGF-axis analytes using ELISA. Logistic regression estimated ORs and 95% confidence intervals for risk of total, low-grade (Gleason 2–6) and high-grade (Gleason 7–10) cancers. Results were stratified by intervention assignment. In both the placebo and finasteride arms, serum IGF1, IGF2, IGFBP3, and the IGF1:IGFBP3 ratio were not associated with prostate cancer. However, men in the highest versus lowest quartile of serum IGFBP2 had a 48% (Ptrend = 0.02) and 55% (Ptrend = 0.01) increased risk for total and low-grade cancers, respectively. These IGFBP2 associations were attenuated and no longer statistically significant in the finasteride arm. Our results suggest that in general, serum IGF-axis analytes were not associated with prostate cancer risk in the PCPT in which presence or absence of all cancers was biopsy-determined. The exception was the finding that high serum IGFBP2 is a risk factor for low-grade disease, which was attenuated for men on finasteride. Further research is needed to understand better the risk incurred by high IGFBP2 and whether androgen-suppressing agents such as finasteride influence aspects of IGFBP2 physiology relevant to prostate carcinogenesis. Cancer Prev Res; 6(2); 91–9. ©2013 AACR.

[1]  P. Nelson,et al.  Interaction of IGF signaling and the androgen receptor in prostate cancer progression , 2006, Journal of cellular biochemistry.

[2]  E. Rimm,et al.  Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[3]  E. Somers.  International Agency for Research on Cancer. , 1985, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[4]  E. Riboli,et al.  Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. , 2000, Journal of the National Cancer Institute.

[5]  H. Ariga,et al.  PAPA-1 Is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions. , 2009, Molecular endocrinology.

[6]  I. Thompson,et al.  Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention , 2008, Cancer Prevention Research.

[7]  J. Kaprio,et al.  Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. , 1996, The Journal of clinical investigation.

[8]  Claude Bouchard,et al.  Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. , 1998, WMJ : official publication of the State Medical Society of Wisconsin.

[9]  A. Whittemore,et al.  Prostate Cancer Risk in Relation to Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3: A Prospective Multiethnic Study , 2008, Cancer Epidemiology Biomarkers & Prevention.

[10]  A. Kristal,et al.  Centralized Blood Processing for the Selenium and Vitamin E Cancer Prevention Trial: Effects of Delayed Processing on Carotenoids, Tocopherols, Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein 3, Steroid Hormones, and Lymphocyte Viability , 2005, Cancer Epidemiology Biomarkers & Prevention.

[11]  M. Kattan,et al.  Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. , 2007, Journal of the National Cancer Institute.

[12]  M. Gleave,et al.  Insulin increases de novo steroidogenesis in prostate cancer cells. , 2011, Cancer research.

[13]  E. Riboli,et al.  Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls , 2003, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[14]  E. Riboli,et al.  Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition , 2008, British Journal of Cancer.

[15]  M. Stampfer,et al.  Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. , 2002, Journal of the National Cancer Institute.

[16]  I. Thompson,et al.  Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. , 2010, American journal of epidemiology.

[17]  S. Chua,et al.  Prostate cancer risk and serum levels of insulin and leptin: a population-based study. , 2001, Journal of the National Cancer Institute.

[18]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[19]  J. Fraumeni,et al.  Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. , 2001, Cancer research.

[20]  L. Murphy,et al.  Free insulin-like growth factor I (IGF-I) in healthy subjects: relationship with IGF-binding proteins and insulin sensitivity. , 1997, The Journal of clinical endocrinology and metabolism.

[21]  Claude Bouchard,et al.  Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: Executive summary , 1998 .

[22]  Ruth E Patterson,et al.  Energy from fat is associated with obesity in U.S. men: results from the Prostate Cancer Prevention Trial. , 2002, Preventive medicine.

[23]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[24]  T. Lohman,et al.  Anthropometric Standardization Reference Manual , 1988 .

[25]  R. Baxter,et al.  Cellular actions of the insulin-like growth factor binding proteins. , 2002, Endocrine reviews.

[26]  T. Rohan,et al.  Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.

[27]  A. Kristal,et al.  Validity of short food frequency questionnaires used in cancer chemoprevention trials: results from the Prostate Cancer Prevention Trial. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[28]  N. Breslow,et al.  Statistical methods in cancer research: volume 1- The analysis of case-control studies , 1980 .

[29]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[30]  M. Stampfer,et al.  Re: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer , 2002 .

[31]  F. Berrino,et al.  Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. , 2007, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[32]  M. Pollak.  The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology , 2012, Clinical Cancer Research.

[33]  Meir J. Stampfer,et al.  Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .

[34]  M. Stampfer,et al.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. , 1998, Science.

[35]  I. Thompson,et al.  Dietary Supplement Use in the Prostate Cancer Prevention Trial: Implications for Prevention Trials , 2001, Nutrition and cancer.

[36]  E. Riboli,et al.  Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition. , 2012, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[37]  P. Walsh.  Dietary supplement use in the Prostate Cancer Prevention trial: implications for prevention trials. , 2003, The Journal of urology.

[38]  D. Albanes,et al.  Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. , 2003, Cancer research.

[39]  H. Adami,et al.  Insulin-like growth factor-binding protein-1 and prostate cancer. , 1999, Journal of the National Cancer Institute.

[40]  E. Metter,et al.  Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. , 2000, The Journal of clinical endocrinology and metabolism.

[41]  I. Thompson,et al.  Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. , 2006, Journal of the National Cancer Institute.

[42]  François G. Meyer,et al.  Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies , 2008, Annals of Internal Medicine.

[43]  S. Horvath,et al.  Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer , 2007, Proceedings of the National Academy of Sciences.